Clinical Trials Using Mogamulizumab

Clinical trials are research studies that involve people. The clinical trials on this list are studying Mogamulizumab. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-3 of 3
  • Mogamulizumab and Pembrolizumab in Treating Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma

    This phase I / II trial studies the best dose and side effects of mogamulizumab in combination with pembrolizumab and to see how well they work in treating patients with diffuse large B cell lymphoma that have come back after a period of improvement (relapsed) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as mogamulizumab and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: 8 locations

  • Recombinant Human IL-15 and Mogamulizumab for the Treatment of Refractory or Relapsed T-Cell Leukemia and Mycosis Fungoides / Sezary Syndrome

    This phase I trial studies the side effects and best dose of recombinant human IL-15 in combination with mogamulizumab in treating patients with T-cell leukemia that has come back (relapsed) or does not respond to treatment (refractory), and mycosis fungoides / Sezary syndrome. IL-15 is a man-made version of a small protein (cytokine) that is naturally produced in the body by certain white blood cells and increases the activity and strength of the immune system. Patients with cancer can have a weak immune system. This weakness can be caused by the cancer itself, or by treatments such as radiation, chemotherapy or other drugs that work against the immune system. It is hoped that IL-15 can “boost” or strengthen the immune system as it fights against cancer. Mogamulizumab is a monoclonal antibody that works by attaching to a protein on tumor cells and marking the tumor cell for destruction by other cells of the immune system. IL-15 may boost the number of immune system cells which are responsible for destroying tumor cells with antibodies (such as mogamulizumab) attached.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Microdevice for In Situ Candidate Drug Screening in Skin Lesions of T-Cell Lymphoma

    This pilot trial studies the side effects and feasibility of microdevice for in situ candidate drug screening in skin lesions of T-cell lymphoma. Implanting and retrieving a microdevice that releases up to 19 drugs directly within a skin lesion may be a possible tool to evaluate the effectiveness of several approved cancer drugs against cutaneous T cell lymphoma or peripheral T cell lymphoma.
    Location: 2 locations